-
IFSC 2024 | Dr. Rafael Bejar Unveils Clonal Hematopoiesis: Concepts, Risks, and New Treatment Strategies
The 9th International Forum on Stem Cells (IFSC) in 2024 focused on basic stem cell research, regenerative medicine, cell therapy, and the application of clinical research guidelines, gathering experts and scholars from around the world to discuss the latest frontiers of scientific discoveries and technological advancements. During the conference, “Hematology Frontier” specially invited Dr. Rafael…
-
Academician Binghe Xu: The Rise of International Collaboration and China’s Role in Breast Cancer Clinical Research
With breast cancer incidence rates on the rise globally, it has become a major health threat to women. In China, the challenge of breast cancer control is equally significant, and improving the quality of diagnosis, treatment, and survival rates for breast cancer patients has become a critical task in healthcare. International cooperation has been a…
-
ESMO 2024丨Antibody-Drug Conjugates (ADCs) Offer Hope for Breast Cancer Patients, Including Those with Brain Metastases
Antibody-drug conjugates have expanded treatment options for patients with unresectable locally advanced or metastatic breast cancer, providing new options for those who have exhausted other treatments. Studies presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona) aimed to expand the current use of ADCs to a wider patient population and…
-
ESMO 2024丨Early Immunotherapy Significantly Extends Overall Survival in Triple-Negative Breast Cancer Patients
The final results of the KEYNOTE-522 trial confirm the potential of pembrolizumab to change patient management, though careful patient selection and toxicity monitoring are essential.
-
ESMO 2024丨Dr. Jakob N. Kather: Does Artificial Intelligence Have a Place in Precision Oncology?
The strength of artificial intelligence (AI) in precision oncology lies in its ability to unlock the value of real-world data from millions of cancer patients. In recent years, AI has empowered oncologists to analyze large datasets from multiple sources, including next-generation sequencing and medical imaging, aiding in cancer characterization and offering a more comprehensive understanding…
-
Dr. Xiangdong Cheng: Prioritizing Patient Needs to Foster Original, China-Specific Research in Gastric Cancer丨CACA Integrative Gastric Cancer
On October 18-19, 2024, the CACA Integrative Gastric Cancer Conference was held in Wuhan, bringing together multidisciplinary experts from around the world to discuss the latest advances, standards, and research developments in gastric cancer diagnosis and treatment.During the conference, Oncology Frontier interviewed Dr. Xiangdong Cheng, Secretary of Zhejiang Cancer Hospital. Professor Cheng shared insights into…
-
ESMO 2024丨Dr. Xiaojie Bian: Optimizing mCRPC Treatment Strategies and Prognostic Analysis Through Biomarkers
For most prostate cancer patients, resistance to androgen deprivation therapy (ADT) inevitably develops within 18-36 months, progressing to castration-resistant prostate cancer (CRPC). This transition not only increases mortality risk but also poses a serious challenge to survival outcomes. The European Society for Medical Oncology (ESMO) Annual Meeting 2024, held from September 13 to 17 in…
-
Welcome to 2024 Chinese Congress of Holistic Integrative Oncology (2024 CCHIO) & 4th International Congress of the Asian Oncology Society (AOS2024)
On behalf of the organizing committee of the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO), we are very pleased to invite you to attend the 2024 CCHIO & 4th International Congress of the Asian Oncology Society (AOS2024) . This esteemed event will be held from November 14-16, 2024, in the historic and culturally rich…
Connecting Medical Expertise through Media